Armstrong Shaw Associates’s Gilead Sciences GILD Stock Holding History

Armstrong Shaw Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$221K	Hold	2,950	–	–	0.23%	41
2023 Q2	$227K	Hold	2,950	–	–	0.23%	44
2023 Q1	$245K	Hold	2,950	–	–	0.24%	44
2022 Q4	$253K	Buy	+2,950	New	+$234K	0.25%	37
2022 Q1	–	Sell	-2,950	Closed	-$214K	–	44
2021 Q4	$214K	Hold	2,950	–	–	0.17%	43
2021 Q3	$206K	Hold	2,950	–	–	0.18%	42
2021 Q2	$203K	Buy	+2,950	New	+$197K	0.18%	43
2020 Q3	–	Sell	-2,950	Closed	-$227K	–	41
2020 Q2	$227K	Hold	2,950	–	–	0.28%	41
2020 Q1	$221K	Buy	+2,950	New	+$204K	0.28%	41
2018 Q4	–	Sell	-2,950	Closed	-$228K	–	40
2018 Q3	$228K	Hold	2,950	–	–	0.2%	41
2018 Q2	$209K	Hold	2,950	–	–	0.19%	43
2018 Q1	$222K	Hold	2,950	–	–	0.2%	40
2017 Q4	$211K	Hold	2,950	–	–	0.18%	41
2017 Q3	$239K	Hold	2,950	–	–	0.22%	39
2017 Q2	$209K	Hold	2,950	–	–	0.08%	41
2017 Q1	$200K	Hold	2,950	–	–	0.05%	42
2016 Q4	$211K	Hold	2,950	–	–	0.05%	44
2016 Q3	$233K	Buy	+2,950	New	+$240K	0.06%	47

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Armstrong Shaw Associates's GILD Position: Q3 2023 in Review

Armstrong Shaw Associates held its Gilead Sciences (GILD) position steady in Q3 2023 at 2,950 shares worth $221K. The position accounts for 0.23% of the portfolio, ranked #41.

Armstrong Shaw Associates first reported a position in GILD in Q3 2016 and has held it in 18 quarters since. The position peaked at $253K in Q4 2022. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

Armstrong Shaw Associates held 2,950 shares of Gilead Sciences worth $221K as of Q3 2023.
Armstrong Shaw Associates left its Gilead Sciences share count unchanged in Q3 2023.
Gilead Sciences made up 0.23% of Armstrong Shaw Associates's portfolio in Q3 2023, its #41 holding.
Armstrong Shaw Associates first reported a position in Gilead Sciences in Q3 2016 and has held it in 18 quarters since.
Armstrong Shaw Associates's Gilead Sciences position peaked at $253K in Q4 2022.
1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Armstrong Shaw Associates's 13F filing for Q3 2023, filed 13 Oct 2023.